NxStage Medical Newswire

NxStage Medical Newswire

Comprehensive Real-Time News Feed for NxStage Medical.

Results 1 - 20 of 444 in NxStage Medical

  1. Monteverde & Associates PC LogoRead the original story w/Photo

    Sunday Sep 10 | PR Newswire

    As a result of the merger, Nxstage Medical shareholders are only anticipated to receive Click here for more information: . It is free and there is no cost or obligation to you.

    Comment?

  2. NxStage Medical, Inc. Expected to Post FY2017 Earnings ofRead the original story w/Photo

    Saturday Sep 9 | Daily Political

    NxStage Medical, Inc. - Analysts at Leerink Swann dropped their FY2017 earnings estimates for NxStage Medical in a report issued on Wednesday. Leerink Swann analyst D. Antalffy now expects that the medical device company will post earnings of per share for the year, down from their previous forecast of .

    Comment?

  3. FY2017 EPS Estimates for NxStage Medical, Inc. Reduced by AnalystRead the original story w/Photo

    Friday Sep 8 | AmericanBankingNews.com

    NxStage Medical, Inc. - Stock analysts at Leerink Swann dropped their FY2017 EPS estimates for NxStage Medical in a research report issued on Wednesday. Leerink Swann analyst D. Antalffy now forecasts that the medical device company will post earnings per share of for the year, down from their previous estimate of .

    Comment?

  4. Research Analysts Issue Forecasts for NxStage Medical, Inc.'s Q2 2018 EarningsRead the original story w/Photo

    Thursday Sep 7 | AmericanBankingNews.com

    NxStage Medical, Inc. - Equities research analysts at Leerink Swann decreased their Q2 2018 earnings per share estimates for NxStage Medical in a research report issued to clients and investors on Wednesday. Leerink Swann analyst D. Antalffy now forecasts that the medical device company will earn $0.01 per share for the quarter, down from their prior forecast of $0.04.

    Comment?

  5. NxStage Medical, Inc. (NXTM) President Sells $27,950.00 in StockRead the original story w/Photo

    Tuesday Sep 5 | IntersportsWire

    NxStage Medical, Inc. President Joseph E. Turk, Jr. sold 1,000 shares of NxStage Medical stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $27.95, for a total value of $27,950.00.

    Comment?

  6. NxStage Medical (NXTM) vs. Novadaq Technologies (NVDQ) Critical AnalysisRead the original story w/Photo

    Sunday Sep 3 | AmericanBankingNews.com

    NxStage Medical and Novadaq Technologies are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability. This is a summary of recent ratings and target prices for NxStage Medical and Novadaq Technologies, as reported by MarketBeat.

    Comment?

  7. NxStage Medical, Inc. (NXTM) Receives $30.00 Consensus Price Target from BrokeragesRead the original story w/Photo

    Saturday Sep 2 | IntersportsWire

    NxStage Medical, Inc. has been assigned an average rating of "Hold" from the ten analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and nine have issued a hold recommendation on the company.

    Comment?

  8. NxStage Medical (NXTM) - Analysts' Weekly Ratings ChangesRead the original story w/Photo

    Thursday Aug 31 | AmericanBankingNews.com

    They now have a $30.00 price target on the stock, up previously from $28.00. 8/11/2017 - NxStage Medical was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.

    Comment?

  9. Birchview Capital LP Buys 6,000 Shares of NxStage Medical, Inc.Read the original story w/Photo

    Thursday Aug 31 | Daily Political

    Birchview Capital LP increased its position in NxStage Medical, Inc. by 21.3% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 34,200 shares of the medical device company's stock after buying an additional 6,000 shares during the period.

    Comment?

  10. Head to Head Survey: Novadaq TechnologiesRead the original story w/Photo

    Wednesday Aug 30 | The Breeze

    Novadaq Technologies and NxStage Medical are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk. Novadaq Technologies has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.

    Comment?

  11. NxStage Medical, Inc. (NXTM) Receives Average Rating of "Hold" from BrokeragesRead the original story w/Photo

    Wednesday Aug 30 | AmericanBankingNews.com

    Shares of NxStage Medical, Inc. have been given a consensus rating of "Hold" by the ten ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and nine have given a hold recommendation to the company.

    Comment?

  12. Head to Head Survey: NxStage MedicalRead the original story w/Photo

    Tuesday Aug 29 | AmericanBankingNews.com

    NxStage Medical and Novadaq Technologies are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership. NxStage Medical has higher revenue and earnings than Novadaq Technologies.

    Comment?

  13. NxStage Medical, Inc. (NXTM) Sees Large Drop in Short InterestRead the original story w/Photo

    Monday Aug 28 | AmericanBankingNews.com

    NxStage Medical, Inc. was the target of a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 2,234,165 shares, a decline of 26.3% from the July 31st total of 3,031,024 shares.

    Comment?

  14. NxStage Medical Announces FDA Clearance for Solo Home Hemodialysis Using NxStage System OneRead the original story

    Monday Aug 28 | PressReleasePoint

    NxStage Medical, Inc. , a leading medical technology company focused on advancing renal care , today announced that the U.S. Food and Drug Administration has cleared its System One for solo home hemodialysis, without a care partner, during waking hours. Since receiving its first clearance for home hemodialysis from the FDA in 2005 and the first and only home nocturnal hemodialysis clearance in 2014, the NxStage System One has provided over 14 million treatments to thousands of patients in their homes around the world, during the day and at night.

    Comment?

  15. NxStage Wins FDA Clearance for Solo Home Hemodialysis Using NxStage System OneRead the original story

    Sunday Aug 27 | BioSpace

    NxStage Medical Announces FDA Clearance for Solo Home Hemodialysis Using NxStageA System Onea - First clearance of its kind gives trained NxStage patients freedom to dialyze without a care partner /PRNewswire/ -- NxStage Medical, Inc. , a leading medical technology company focused on advancing renal care , today announced that the U.S. Food and Drug Administration has cleared its System One for solo home hemodialysis, without a care partner, during waking hours.

    Comment?

  16. NxStage System One Now In Nine Of Top Ten U.S. Nephrology HospitalsRead the original story

    Thursday Aug 24 | BioSpace

    , Aug. 24, 2017 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care , today announced that the NxStageA System One is now used in nine of the top ten nephrology hospitals in , and ...

    Comment?

  17. NxStage Medical, Inc. (NXTM) SVP Sells $125,646.00 in StockRead the original story w/Photo

    Wednesday Aug 23 | AmericanBankingNews.com

    NxStage Medical, Inc. SVP Matthew W. Towse sold 4,300 shares of the business's stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $29.22, for a total transaction of $125,646.00.

    Comment?

  18. Contrasting NxStage MedicalRead the original story w/Photo

    Aug 21, 2017 | AmericanBankingNews.com

    NxStage Medical and Novadaq Technologies are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership. 91.8% of NxStage Medical shares are held by institutional investors.

    Comment?

  19. NxStage Medical (NXTM) - Investment Analysts' Recent Ratings ChangesRead the original story w/Photo

    Aug 18, 2017 | IntersportsWire

    According to Zacks, "NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. " 8/11/2017 - NxStage Medical was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.

    Comment?

  20. BidaskClub Downgrades NxStage Medical, Inc. (NASDAQ:NXTM) to SellRead the original story w/Photo

    Aug 18, 2017 | IntersportsWire

    Other analysts have also recently issued reports about the company. Northland Securities reiterated a buy rating and issued a $35.00 target price on shares of NxStage Medical in a report on Monday, April 3rd.

    Comment?